Mobile Trading

BAL PHARMA LTD.

NSE : BALPHARMABSE : 524824ISIN CODE : INE083D01012Industry : Pharmaceuticals & DrugsHouse : Private
BSE94.80-1.4 (-1.46 %)
PREV CLOSE ( ) 96.20
OPEN PRICE ( ) 96.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 747
TODAY'S LOW / HIGH ( )93.50 96.20
52 WK LOW / HIGH ( )76.3 157.9
Select year
ParticularsMar2024Mar2023Mar2022Mar2021Mar2020
Operational & Financial Ratios
   Earnings Per Share (Rs)4.681.643.793.20-8.62
   CEPS(Rs)11.087.499.959.60-3.68
   DPS(Rs)1.201.001.001.000.00
   Book NAV/Share(Rs)43.8440.6638.9235.5236.99
   Tax Rate(%)17.7044.8437.87-14.864.71
Margin Ratios
   Core EBITDA Margin(%)9.358.308.539.842.94
   EBIT Margin(%)7.225.617.146.49-0.47
   Pre Tax Margin(%)2.671.563.271.64-7.91
   PAT Margin (%)2.190.862.031.88-7.53
   Cash Profit Margin (%)5.163.865.245.68-3.05
Performance Ratios
   ROA(%)2.370.922.281.97-5.16
   ROE(%)11.194.3110.348.97-21.65
   ROCE(%)12.139.5612.339.72-0.44
   Asset Turnover(x)1.081.061.121.050.68
   Sales/Fixed Asset(x)2.562.552.602.471.83
   Working Capital/Sales(x)10.9116.1614.8621.57-80.59
Efficiency Ratios
   Fixed Capital/Sales(x)0.390.390.390.400.55
   Receivable days104.16101.5692.4885.08121.92
   Inventory Days99.97103.4287.4793.31146.63
   Payable days162.36165.90132.11111.21207.25
Valuation Parameters
   PER(x)19.5140.8328.4916.800.00
   PCE(x)8.238.9410.845.60-8.85
   Price/Book(x)2.081.652.771.510.88
   Yield(%)1.321.490.931.860.00
   EV/Net Sales(x)0.800.750.920.740.94
   EV/Core EBITDA(x)7.838.728.867.2123.47
   EV/EBIT(x)11.0513.3912.8511.43-202.40
   EV/CE(x)1.301.170.990.770.68
   M Cap / Sales0.430.350.570.320.27
Growth Ratio
   Net Sales Growth(%)11.518.1812.2546.43-23.96
   Core EBITDA Growth(%)31.95-10.0912.99274.74-63.19
   EBIT Growth(%)43.52-15.0823.562138.47-106.36
   PAT Growth(%)184.26-54.0921.07136.55-698.78
   EPS Growth(%)185.36-56.7018.33137.11-422.55
Financial Stability Ratios
   Total Debt/Equity(x)2.012.051.802.092.26
   Current Ratio(x)1.151.091.111.080.99
   Quick Ratio(x)0.720.620.670.690.57
   Interest Cover(x)1.591.391.841.34-0.06
   Total Debt/Mcap(x)0.971.250.651.382.57

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.